Oxford Biomedica

Oxford, UK
Hybrid — also manufactures internal programs
Lentiviral AAV
7 confirmed programs · 3 sponsors · Last scored 2026-03-15
66.7
Signal Score
○ FDA Inspections ✓ Clinical Trials (7) ○ SEC Filings ✓ Press (18)

Quick Facts: Oxford Biomedica

Signal Score
66.7/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Oxford, UK
Modalities
Lentiviral, AAV
Active CGT Programs
7 confirmed from ClinicalTrials.gov across 3 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 65.4
7 active programs across 3 sponsors
Modalities: Lentiviral, AAV
6 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
7 active programs across 3 sponsors · Modalities: Lentiviral, AAV · 6 programs in advanced phases (Phase 2/3)
Programs 7
Sponsors3
ModalitiesLentiviral, AAV
7 active programs across 3 sponsors
Modalities: Lentiviral, AAV
6 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT01856439 Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease PHASE1/PHASE2 Terminated
NCT01301443 Phase I Dose Escalation Safety Study of RetinoStat in... PHASE1 Completed
NCT00627588 Phase I/II Study of the Safety, Efficacy and Dose Evaluation... PHASE1/PHASE2 Completed
NCT00397345 TroVax Renal Immunotherapy Survival Trial PHASE3 Completed
NCT00445523 Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha... PHASE2 Completed
NCT00325507 Safety and Biological Activity of TroVax® Vaccine Given With... PHASE2 Completed
NCT00083941 A Study of TroVax Vaccine Given in Conjunction With IL-2 for... PHASE2 Completed
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability 75.0
Publicly traded — financial transparency
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
Capacity 60.0
1 CGT manufacturing site: Oxford, UK
Modalities: Lentiviral, AAV
Capacity assessment: 60.0/100
Sites: Oxford, UK
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
StatusAvailable
1 CGT manufacturing site: Oxford, UK
Modalities: Lentiviral, AAV
Capacity assessment: 60.0/100
Sites: Oxford, UK
Recent Press18 articles
1 CGT manufacturing site: Oxford, UK
Modalities: Lentiviral, AAV
Capacity assessment: 60.0/100

Recent News 18 articles

general 2026-03-18
Oxford Biomedica Signs Licensing Deal with Australia’s VVMF - Contract Pharma
Oxford Biomedica Signs Licensing Deal with Australia’s VVMF  Contract Pharma
Source →
general 2026-03-18
Oxford Biomedica PLC and Viral Vector Manufacturing Facility Enter Licensing Agreement - marketscreener.com
Oxford Biomedica PLC and Viral Vector Manufacturing Facility Enter Licensing Agreement  marketscreener.com
Source →
general 2026-03-18
Oxford Biomedica reaches licensing agreement with Australia's VVMF - Sharecast.com
Oxford Biomedica reaches licensing agreement with Australia's VVMF  Sharecast.com
Source →
general 2026-03-18
Oxford Biomedica licenses viral vector platforms to Australian CDMO VVMF - TipRanks
Oxford Biomedica licenses viral vector platforms to Australian CDMO VVMF  TipRanks
Source →
general 2026-03-18
IN BRIEF: Oxford Biomedica inks new licensing and option deal - London South East
IN BRIEF: Oxford Biomedica inks new licensing and option deal  London South East
Source →
general 2026-03-18
Oxb enters into licensing agreement with viral vector manufacturing facility (Vvmf), providing access to its AAV and LV viral vector platforms - marketscreener.com
Oxb enters into licensing agreement with viral vector manufacturing facility (Vvmf), providing access to its AAV and LV viral vector platforms  marketscreener.com
Source →
general 2026-03-09
Oxford Biomedica Share Admission Update Highlights Role Within FTSE 350 - Kalkine Media
Oxford Biomedica Share Admission Update Highlights Role Within FTSE 350  Kalkine Media
Source →
general 2026-03-03
Oxford Biomedica Confirms Total Voting Rights at 120.9 Million Shares - The Globe and Mail
Oxford Biomedica Confirms Total Voting Rights at 120.9 Million Shares  The Globe and Mail
Source →
general 2026-02-28
Valuation differences halt EQT’s Oxford Biomedica takeover push - pe-insights.com
Valuation differences halt EQT’s Oxford Biomedica takeover push  pe-insights.com
Source →
general 2026-02-25
Oxford Biomedica rejects EQT approaches as suitor walks away - TipRanks
Oxford Biomedica rejects EQT approaches as suitor walks away  TipRanks
Source →
general 2026-02-25
Oxford Biomedica hits top-end 2025 guidance and turns EBITDA positive - The Globe and Mail
Oxford Biomedica hits top-end 2025 guidance and turns EBITDA positive  The Globe and Mail
Source →
general 2026-02-25
EQT backs out of takeover bid for UK's Oxford Biomedica - Reuters
EQT backs out of takeover bid for UK's Oxford Biomedica  Reuters
Source →
general 2026-02-24
Oxford BioMedica (LSE:OXB) Shares Drop Ahead of EQT Deadline - Kalkine Media
Oxford BioMedica (LSE:OXB) Shares Drop Ahead of EQT Deadline  Kalkine Media
Source →
general 2026-02-13
AAV Packaging Services Market Projected to Reach USD 3.8 Billion - openPR.com
AAV Packaging Services Market Projected to Reach USD 3.8 Billion  openPR.com
Source →
partnership 2026-02-04
OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts - Fierce Pharma
OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts  Fierce Pharma
Source →
financial 2026-02-04
Key facts: Bristol Myers Squibb Q4 net income rises; signs deal with Oxford BioMedica; Piper Sandler raises price target - TradingView
Key facts: Bristol Myers Squibb Q4 net income rises; signs deal with Oxford BioMedica; Piper Sandler raises price target  TradingView
Source →
general 2026-02-04
Oxford Biomedica signs expanded CAR‑T supply pact with Bristol Myers Squibb - Sharecast.com
Oxford Biomedica signs expanded CAR‑T supply pact with Bristol Myers Squibb  Sharecast.com
Source →
general 2026-02-03
Oxford Biomedica Confirms Total Voting Rights at 120.8 Million Shares - The Globe and Mail
Oxford Biomedica Confirms Total Voting Rights at 120.8 Million Shares  The Globe and Mail
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Lentiviral CDMOs → AAV CDMOs →